# PD-L2 deficiency in Alveolar macrophages drives fibrosis, apoptosis, and ferroptosis via M1 polarization in connective tissue disease-associated interstitial lung disease

**Authors:** Junhui Lu, Xiuyuan Feng, Xin Chang, Wei Cheng, Pengfei Pan, Jian Wu

PMC · DOI: 10.1007/s10238-026-02115-5 · Clinical and Experimental Medicine · 2026-03-13

## TL;DR

Low PD-L2 in lung macrophages worsens lung disease by causing harmful immune responses and cell damage in connective tissue disease patients.

## Contribution

This study reveals PD-L2's role in macrophage polarization and fibroblast responses in CTD-ILD, suggesting it as a potential therapeutic target.

## Key findings

- CTD-ILD patients had lower serum PD-L2 levels, which correlated with increased lung fibrosis.
- PD-L2 deficiency in macrophages promoted M1 polarization and induced fibroblast apoptosis and ferroptosis.
- PD-L2 knockout mice showed altered ferroptosis markers and reduced CD206+ macrophages after lung injury.

## Abstract

Macrophages play a pivotal role in modulating immune responses in connective tissue disease-associated interstitial lung disease (CTD-ILD). The role of programmed death ligand-2 (PD-L2), an immune checkpoint molecule expressed on macrophages, in macrophage polarization in CTD-ILD remains poorly understood. Serum PD-L2 levels were measured in CTD-ILD patients, CTD-nonILD patients, and healthy controls. Alveolar macrophages (AMs) were transfected with PD-L2-targeting shRNA or control constructs, and their effects on macrophage phenotype and fibroblast fate were evaluated. M1/M2 polarization was assessed by RT-PCR, Western blotting, and flow cytometry. Human embryonic lung fibroblasts (HELFs) were co-cultured or treated with macrophage-conditioned media, and assays for cell viability, apoptosis, fibrosis, and ferroptosis were performed. A bleomycin (BLM)-induced CTD-ILD mouse model was used to evaluate the effects of PD-L2 knockout on lung fibrosis and ferroptosis markers. Serum PD-L2 levels were significantly lower in CTD-ILD patients compared with CTD-nonILD patients and healthy controls, and negatively correlated with the extent of lung fibrosis. In vitro, PD-L2 knockdown in AMs promoted M1 polarization, suppressed M2 related markers, and induced fibroblast apoptosis, fibrosis, and ferroptosis. Conditioned media from PD-L2-deficient macrophages produced similar effects. In vivo, PD-L2 knockout mice exhibited decreased numbers of CD206+ macrophages and regulated ferroptosis markers (ACSL4 upregulation, GPX4 and FTH1 downregulation) in lung tissues following BLM treatment. This study identifies PD-L2 as an important regulator of macrophage polarization and fibroblast responses in CTD-ILD. Our findings suggest that serum PD-L2 levels may reflect disease severity, and that restoring PD-L2 function could represent a potential therapeutic direction warranting further investigation in preclinical models.

The online version contains supplementary material available at 10.1007/s10238-026-02115-5.

## Linked entities

- **Genes:** PDCD1LG2 (programmed cell death 1 ligand 2) [NCBI Gene 80380], ACSL4 (acyl-CoA synthetase long chain family member 4) [NCBI Gene 2182], GPX4 (glutathione peroxidase 4) [NCBI Gene 2879], FTH1 (ferritin heavy chain 1) [NCBI Gene 2495], MRC1 (mannose receptor C-type 1) [NCBI Gene 4360]
- **Proteins:** PDCD1LG2 (programmed cell death 1 ligand 2), ACSL4 (acyl-CoA synthetase long chain family member 4), GPX4 (glutathione peroxidase 4), FTH1 (ferritin heavy chain 1), MRC1 (mannose receptor C-type 1)
- **Chemicals:** bleomycin (PubChem CID 5360373)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, Gpx4 (glutathione peroxidase 4) [NCBI Gene 625249] {aka GPx-4, GSHPx-4, PHGPx, mtPHGPx, snGPx}, ACSL4 (acyl-CoA synthetase long chain family member 4) [NCBI Gene 2182] {aka ACS4, FACL4, LACS4, MRX63, MRX68, XLID63}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, ARG1 (arginase 1) [NCBI Gene 383], FTH1 (ferritin heavy chain 1) [NCBI Gene 2495] {aka FHC, FTH, FTHL6, HFE5, NBIA9, PIG15}, Pdcd1lg2 (programmed cell death 1 ligand 2) [NCBI Gene 58205] {aka B7-DC, Btdc, F730015O22Rik, PD-L2}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Lxn (latexin) [NCBI Gene 17035], IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, BLNK (B cell linker) [NCBI Gene 29760] {aka AGM4, BASH, BLNK-S, LY57, SLP-65, SLP65}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, Fth1 (ferritin heavy polypeptide 1) [NCBI Gene 14319] {aka FHC, Fth, HFt, MFH}, VIM (vimentin) [NCBI Gene 7431], Acsl4 (acyl-CoA synthetase long-chain family member 4) [NCBI Gene 50790] {aka 9430020A05Rik, ACS4, Facl4, Lacs4}, PDCD1LG2 (programmed cell death 1 ligand 2) [NCBI Gene 80380] {aka B7DC, Btdc, CD273, PD-L2, PDCD1L2, PDL2}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, ISYNA1 (inositol-3-phosphate synthase 1) [NCBI Gene 51477] {aka INO1, INOS, IPS, IPS 1, IPS-1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}
- **Diseases:** MCTD (MESH:D008947), SSc (MESH:D012595), RA (MESH:D001172), Inflammatory (MESH:D007249), COPD (MESH:D029424), IMNM (MESH:C567355), fibrotic lung disease (MESH:D008171), sarcoidosis (MESH:D012507), DM (MESH:D003882), parasitic infections (MESH:D010272), PM (MESH:D017285), COVID-19 infection (MESH:D000086382), impairment in lung function (MESH:D003072), autoimmune-related lung injury (MESH:D055370), heart failure (MESH:D006333), pSS (MESH:D012859), pulmonary hypertension (MESH:D006976), post-COVID-19 (MESH:D000094024), tissue injury (MESH:D017695), fibrosis (MESH:D005355), hepatic/renal insufficiency (MESH:D048550), radiation pneumonitis (MESH:D017564), cancer (MESH:D009369), UCTD (MESH:D000074079), pneumoconiosis (MESH:D011009), pulmonary infections (MESH:D012141), SLE (MESH:D008180), CTD (MESH:D003240), infection (MESH:D007239), CTD-associated ILD (MESH:D017563), IIM (MESH:D009220)
- **Chemicals:** lipid (MESH:D008055), HEPES (MESH:D006531), PMA (MESH:D013755), BLM (MESH:D001761), water (MESH:D014867), polyacrylamide (MESH:C016679), Trizol (MESH:C411644), LPS (MESH:D008070), CCK-8 (MESH:D012844), CO2 (MESH:D002245), FITC (MESH:D016650), DAPI (MESH:C007293), Iron (MESH:D007501), SDS (MESH:D012967), L-glutamine (MESH:D005973), SYBR  Green (MESH:C098022), PI (MESH:D010716), CCK (MESH:D002766), Dulbecco's modified Eagle's medium (-), PVDF (MESH:C024865)
- **Species:** Capillaria hepatica [taxon 1239592], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** P0018M, C with a 12
- **Cell lines:** fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), HELFs — Homo sapiens (Human), Finite cell line (CVCL_2492), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), HELF — Homo sapiens (Human), Finite cell line (CVCL_C120)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13013153/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13013153/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC13013153/full.md

---
Source: https://tomesphere.com/paper/PMC13013153